



To: Patki Hospital-Kolhapur

E Ward, 3 rd Lane, Shahupuri

Kolhapur - 416001 Contact: 7045689702

Report Of: Mrs. NEHA VISHAL SHETE

Pt. Contact: 8855884819



Sample ID	2200097473
Patient ID	1002255691
Received on	02/08/2022 15:21
Registered on	03/08/2022 17:48
Reported on	04/08/2022 09:53
Referred by	DR.SATISH PATKI
Sonography by	DR.SEEMA SULTANE

# EVICOSCREEN - EVIDENCE BASED COMPREHENSIVE PRENATAL SCREENING REPORT

Patient Name: Mrs. NEHA VISHAL SHETE Patient DOB: 07/07/1994 City: KOLHAPUR

Sample Type:Serum

Ethnicity: Asian

Risk assessment: Algorithm validated by SURUSS 2003, N.J Wald


Hospital ID:

Method:Chemiluminescence

EVIC Screen is an evidence based prenatal screening program curated by Lilac Insights in accordance with the international guidelines for prenatal screening to determine the probability of most common chromosomal aneuploidies in a pregnancy. It utilizes:

- Hormonal values from the pregnancy measured on Fetal Medicine foundation (UK) accredited analyzers and reagents
- Robust indigenous medians from over 5 lac+ pregnancies for different gestation ages
- Risk calculations from evidence based algorithms validated through large international studies
- External audit of the prenatal screening program by United Kingdom National External Quality Assessment Service (UKNEQAS) scheme and Randox International Quality Assessment Scheme (RIQAS)





### INTERPRETATION

The Quadruple Screening for the given sample is found SCREEN NEGATIVE.

# **SUGGESTIONS AND OTHER FINDINGS**


In view of the raised serum free  $\beta$ hCG, fetal growth scan is suggested at 28 - 30 weeks in addition to their routine antenatal care.











Verified by Dr. Suresh Bhanushali MD (Path), Consultant Pathologist of 3





Patient name: Mrs. NEHA VISHAL SHETE Sample ID: 2200097473

				PREGNANCY	DETAILS					
No. of fetuse	s	:1		EDD	:21/12/2022	Age at Te	rm : 28.4	Years		
GA is Based o	on	: HC 168mm at 01	/08/2022	LMP Date	: 13/03/2022	LMP Cert	LMP Certainty : Regular			
Smoking: No	Smoking: None Parity:		Height	:	Weight : 59.00 Kg					
FHR :										
Previous pregnancy history			Pre-ecla	Pre-eclampsia history			Other findings			
Down syndrome Edwards' syndrome			PE in prev	PE in previous pregnancy		Insulin dependent diabetes				
Patau syndrome NTD syndrome			Pat. mother had PE		Chronic hypertension					
EDD: Estimated Due Date   GA: Gestation Age   LMP: Last Menstrual Period   FHR: Fetal Heart Rate   NTD: Neural Tube Defect   PE: Pre-eclampsia   DOB: Date										
of Birth										
SPECIMEN DETAILS										
Sample ID		: 2200097473	CRL	:	Test Name	Conc.	Unit	Corr. Mom		
Collection Da	ate	:01/08/2022	CRL2	:	Free-ß-hCG	17.41	ng/mL	2.16		
Scan Date		:01/08/2022	BPD	: 44.8 mm	AFP	83.48	ng/mL	1.39		
GA at Coll Da	ate	: 19 Weeks 5 Days	BPD2	:	uE3	10.72	nmol/L	1.52		
GA at Scan D	ate	: 19 Weeks 5 Days	HC	: 168 mm	Inhibin A	223.17	pg/mL	1.05		
Received on		:02/08/2022	HC2	:						
GA: Gestation Age   CRL: Crown Rump Length   BPD: Bi-parietal Diameter   HC: Head Circumference   free-ß-hCG: free-Beta Human Chorionic Gonadotropin										
NT: Nuchal Translucency   PAPP-A: Pregnancy-associated Plasma Protein-A										
RISKS										
Disorder: Down Syndrome				Resi	ult:	Low Risk 🛑				
Final risk:	1:1000	000	Age risk:	1:1100						
Cutoff	1:250		Risk type	Risk At Term						
Disorder: Edwards' Syndrome Result: Low Risk								k 🌑		
Final risk:	1:1000	000	Age risk:	1:8000						
Cutoff	1:100		Risk type	Risk At Term						
Neural tube / Abdominal wall defect Result: Low Risk										
Final risk:	-		Age risk:							



2.5

Cutoff



Risk at Term

Risk type







Patient name: Mrs. NEHA VISHAL SHETE Sample ID: 2200097473

## PRENATAL SCREENING BACKGROUND

Every pregnant woman carries a certain degree of risk that her fetus/baby may have certain chromosomal defect/ abnormalities. Diagnosis of these fetal chromosomal abnormalities requires confirmatory testing through analysis of amniocytes or Chorionic Villous Samples (CVS). However, amniocentesis and CVS procedures carry some degree of risk for miscarriage or other pregnancy complications (Tabor and Alfirevic, 2010). Therefore in routine practice, prenatal screening tests are offered to a pregnant woman to provide her a personalised risk for the most common chromosomal abnormalities (T21-Down syndrome, T18- Edwards' syndrome, T13- Patau syndrome) using her peripheral blood sample. Based on this risk assessment, if the risk is high or intermediate, you can take informed decision of opting for invasive procedure such as amniocentesis or CVS followed by confirmatory diagnostic test(s), as per discussion with your clinician.

#### PRENATAL SCREENING TESTS ARE NOT CONFIRMATORY TESTS. THEY ARE LIKELIHOOD ASSESSMENT TESTS.

You may get your prenatal screening result as either of the following:-

High Risk

**High Risk or Screen Positive Result:** A High Risk Result does not mean that the pregnancy is affected with the condition. It means that the likelihood of the pregnancy having a condition is higher than the cut-off (Most commonly used cut-off is 1:250 and this represents the risk of pregnancy loss from confirmatory testing through CVS or amniocentesis).

Low Risk

**Low Risk or Screen Negative Result:** A Low Risk result does not mean that the pregnancy is not affected with a condition. It means that the likelihood of the pregnancy having a condition is lower than the cut-off.

#### SIGNIFICANCE OF MULTIPLE OF MEDIANS (MoMs)

Prenatal Screening determines the likelihood of the pregnancy being affected with certain conditions by analysing levels of certain hormones. These hormones are Feto placental products (released by Fetus or placenta). Their levels not only indicate propensity of the fetus being affected with certain chromosomal conditions, they also provide indication of placental insufficiency that can potentially lead to pregnancy complications like Pre-Eclampsia or Intra-Uterine Growth Restriction. It is therefore important to take cognisance of the Reported MoMs alongside the Risk results.

For more information, visit our website at: www.lilacinsights.com/faq-pns

### **DISCLAIMERS**

#### Limitations of the Test:

As prenatal screening tests are not confirmatory diagnostic tests, the possibility of false positive or false negative results can not be denied. The results issued for this test does not eliminate the possibility that this pregnancy may be associated with other chromosomal or sub- chromosomal abnormalities, birth defects and other complications.

Nuchal Translucency is the most prominent marker in screening for Trisomy 13, 18, 21 in the first trimester and should be measured in accordance with the Fetal Medicine Foundation (UK) guidelines. Nuchal Translucency or Crown Rump Length measurement, if not performed as per FMF (UK) imaging guidelines may lead to erroneous risk assessments and Lilac Insights bears no responsibility for errors arising due to sonography measurements not performed as per these criteria defined by international bodies such as FMF (UK), ISUOG.

It is assumed that the details provided along with the sample are correct. The manner in which this information is used to guide patient care is the responsibility of the healthcare provider, including advising for the need for genetic counselling or additional diagnostic testing like amniocentesis or Chorionic Villus Sampling. Any diagnostic test should be interpreted in the context of all available clinical findings. As with any medical test, there is always a chance of failure or error in sample analysis though extensive measures are taken to avoid these errors.

#### Note:

- Quality of the Down's Syndrome & ONTD screening program (Biochemical values, MoMs and Risk assessments) monitored by UKNEQAS on an ongoing basis.
- This interpretation assumes that patient and specimen details are accurate and correct.
- Lilac Insights does not bear responsibility for the Ultra sound measurements.
- This is a risk estimation test and not a diagnostic test. An increased risk result does not mean that the fetus is affected and a low risk result does not mean that the fetus is unaffected. Reported risks should be correlated and adjusted according to the absence/presence of sonographic markers observed in the anomaly/malformation scan.
- The above risk has been calculated based on Biochemistry values alone.
- It must be clearly understood that the results represent risk and not diagnostic outcomes. Increased risk does not mean that the baby is affected and further tests must be performed before a firm diagnosis can be made. A low risk result does not exclude the possibility of Down's Syndrome or other abnormalities, as the risk assessment does not detect all affected pregnancies.

**END OF REPORT** 



